Loading
A phase 3 trial of Sacituzumab govitecan, Eribulin, Capecitabine, Gemcitabine and Vinorelbine in advanced solid tumours, run by Gilead Sciences, active and no longer recruiting.
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) is a phase 3 interventional study registered as NCT04639986 by Gilead Sciences, with 331 participants enrolled, started 2020-11-23 and due to reach its primary completion in 2026-12. Interventions recorded: Sacituzumab Govitecan-hziy, Eribulin Mesylate Injection, Capecitabine Oral Product, Gemcitabine Injection and Vinorelbine injection.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Eribulin, Topoisomerase-I inhibitors (and ADC payloads), Capecitabine, Gemcitabine and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Capecitabine and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.